Page 118 - MBCA_FULL REPORT_FINAL_FOR_WEB

Study Drug(s) Target Biomarkers/ Combination Sponsor
Subtype
Active, not recruiting Rintatolimod/HER2 Pep- ERB2 HER2+ GM-CSF vs. Ampligen University of Washington
tide Vaccine as adjuvant
Chimeric (trastuzumab- ERB2 HER2+ Ohio State Comprehensive
like/pertuzumab-like) Cancer Center
HER-2 B-cell peptide
vaccine
Allogeneic GM-CSF–se- Tumor anti- Hormone+_HER2- cyclophosphamide Sidney Kimmel Cancer Center
creting breast cancer gens
vaccine/trastuzumab
Active, not recruiting Genetically modified NY-ESO-1 All Proleukin, cyclophos- National Cancer Institute
lymphocytes phamide, fludarabine
HER2 VRP ERB2 HER2+ Duke University
Immunomodulators Imiquimod TLR7 (Toll-like All Radiation National Cancer Institute
receptor 7)
Terminated as of 8/1 Natural killer cells Immunother- All Chemotherapy Investigator-initiated
apy
NLG919 IDO Pathway All NewLink Genetics
Indoximod IDO Pathway Hormone+_HER2- Docetaxel NewLink Genetics
Active, not recruiting Agatolimod TLR9 HER2+ Trastuzumab Pfizer
CC-122 Pleiotropic All Celgene
pathway
MK-3475 PD-1 (pro- TripleNegative Merck
grammed
death 1)
PLX3397 CSF-1 receptor All Paclitaxel Plexxikon
(Fms)
Cyroablation (proce- Immune sys- Hormone+_HER2- John Wayne Cancer Institute
dure) tem at Saint John's Health Center

Other
Heat Shock Protein Ganetespib Hsp90 HER2+ Synta Pharmaceuticals
(Hsp)
Ganetespib Hsp90 Hormone+_HER2- Fulvestrant Dana-Farber/Harvard Cancer
Center
Ganetespib Hsp90 All Paclitaxel, traztu- New York University
zumab
SNX-5422 Hsp90 HER2+ Esanex Incorporated
Other Dasatinib BCR-ABL ty- All Paclitaxel Sloan Kettering
rosine kinase
PF-06647263 Not disclosed All Pfizer
Multiple drugs Mutlple targets All National Cancer Institute
Subtotal Targeted
Non-Targeted
Therapies
Cancer Stem Cells BBI608 Cancer stem All Paclitaxel Boston Biomedical
cells
POL6326 CXCR4 recep- Hormone+_HER2- Eribulin Polyphor
tors
Chloroquine Cancer stem All Paclitaxel, docetaxel, Methodist Hospital Houston
cells nab-paclitaxel, or
ixabepilone
Vantictumab Cancer stem HER2- Paclitaxel OncoMed Pharmaceuticals
cells
Arginine ADI-PEG 20 Arginine HER2- Doxorubicin Polaris Group
Chemotherapy
Active, not recruiting Pemetrexed All